

29th April 2022

To,

Medicines Patent Pool,

Rue de Varembé 7

Geneva 1202

Switzerland

Attention: General Counsel

Subject: Request for termination of the sublicense agreement for Molnupiravir

Dear Sir / Madam,

We request you to kindly accept our submission to terminate our sublicense agreement for Molnupiravir due to commercial reasons.

We sincerely regret and thank you for your kind understanding.

Your Sincerely,

For Lupin Limited

(Mukul Jerath

Vice President, Lupin Limited)